Table 6.

Comparisons of mean (CV) pharmacokinetic parameters of lonafarnib following multiple-dose administration of 100 mg lonafarnib alone in previous phase I studies (12, 19) or in combination with paclitaxel

StudyDose*nCmax, ng/mLAUC(0-12 h), ng·h/mL
This study100 + 606929 (77)7,535 (93)
This study100 + 804919 (61)7,672 (71)
Khuri et al. (12)100 + 1353760 (25)5,550 (51)
Khuri et al. (12)100 + 1758960 (40)8,789 (32)
Previous phase I (19)10061,012 (49)8,773 (67)
  • * Lonafarnib dose (mg) twice daily + paclitaxel dose (mg/m2).

  • n = 6.

  • Lonafarnib alone dose (mg).